A team of scientists at Nagoya University announced on June 11, 2026 a new, minimally invasive tool for cancer screening. The device uses zinc‑oxide nanowires coated with antibodies to pull extracellular vesicles from blood samples. Researchers demonstrated its ability to isolate tumor‑derived vesicles from the serum of ovarian‑cancer patients.
The platform works by guiding nanowires through a microfluidic channel where they encounter circulating vesicles. Antibodies on the nanowire surface bind specifically to proteins displayed on tumor‑derived vesicles, allowing selective capture. Once bound, the nanowires are withdrawn, and the vesicles are released intact for downstream RNA analysis. The method preserves the full complement of microRNAs inside each vesicle, a feat that conventional isolation techniques often miss.
Lead researcher Dr Yuki Tanaka described the breakthrough as „a leap forward in liquid‑biopsy technology.” He noted that zinc‑oxide nanowires provide a high surface‑area platform, increasing capture efficiency without damaging the vesicles. In laboratory tests, the device retrieved over 95 % of target vesicles from spiked serum samples. Subsequent sequencing revealed that the captured microRNA profiles matched those of tumor tissue, confirming the fidelity of the isolation.
The team compared the nanowire method with standard ultracentrifugation and polymer‑based kits. The nanowire approach required less than ten minutes of processing time, whereas traditional methods took several hours. Moreover, the new device required only a few microliters of blood, making it suitable for routine screening.
Ovarian cancer often goes undetected until late stages because early symptoms are vague. Current diagnostic tools rely on imaging and invasive biopsies, which can miss small tumors. By detecting tumor‑specific microRNAs in blood, the nanowire device could flag disease before it becomes clinically apparent.
Preliminary clinical data from 30 ovarian‑cancer patients showed that the nanowire assay identified disease with 92 % sensitivity and 88 % specificity. Dr Tanaka cautioned that larger trials are needed, but the early results suggest a path toward non‑invasive, population‑wide screening. If validated, the technology could be adapted to other cancers that shed characteristic vesicles into circulation.
The researchers plan to integrate the nanowire capture module with portable sequencing units, aiming for point‑of‑care deployment within the next five years. Such a system could bring rapid, accurate cancer detection to clinics lacking advanced laboratory infrastructure.
How does the nanowire device differ from existing liquid‑biopsy methods? It uses antibody‑functionalized zinc‑oxide nanowires to capture whole extracellular vesicles quickly, preserving internal microRNAs that other methods often degrade.
Is the test ready for clinical use? Not yet. The device has shown promise in pilot studies, but larger clinical trials are required to confirm safety and effectiveness.
Can the technology be applied to cancers other than ovarian? Yes. The antibody coating can be swapped to target vesicle markers from different tumor types, potentially enabling a universal cancer‑screening platform.